These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28300852)

  • 61. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
    Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate.
    Mohanna MT; Hofbauer GF
    Dermatology; 2016; 232 Suppl 1():14-6. PubMed ID: 27513957
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
    Erlendsson AM
    Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
    Nisticò S; Del Duca E; Torchia V; Gliozzi M; Bottoni U; Muscoli C
    Int J Immunopathol Pharmacol; 2018; 32():2058738418757925. PubMed ID: 29442526
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Jedlowski PM
    J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects.
    Saraiva MIR; Portocarrero LKL; Vieira MAHB; Swiczar BCC; Westin AT
    An Bras Dermatol; 2018; 93(4):529-534. PubMed ID: 30066759
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Monitoring Ingenol Mebutate Gel Treatment of Actinic Keratoses by Reflectance Confocal Microscopy.
    López Estebaranz JL; Pampín Franco A; Gamo Villegas R; Floristán U
    Acta Derm Venereol; 2017 May; 97(5):646-648. PubMed ID: 28093603
    [No Abstract]   [Full Text] [Related]  

  • 69. New Topical Treatment Options for Actinic Keratosis: A Systematic Review.
    Stockfleth E; Sibbring GC; Alarcon I
    Acta Derm Venereol; 2016 Jan; 96(1):17-22. PubMed ID: 26068001
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis.
    Goldenberg G; Berman B
    Clin Cosmet Investig Dermatol; 2015; 8():1-8. PubMed ID: 25565875
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The use of ingenol mebutate to treat actinic keratosis in standard clinical practice: a prospective phase IV multicenter observational cohort study.
    Platsidaki E; Kostopoulos N; Panagakis P; Cheliotis G; Antoniou C; Kontochristopoulos G
    Int J Dermatol; 2020 Jun; 59(6):690-697. PubMed ID: 32301503
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sequential treatment of actinic keratosis with cryotherapy and ingenol mebutate: reflectance confocal microscopy monitoring of efficacy and local skin reaction.
    Pasquali P; Segurado-Miravalles G; González S
    Int J Dermatol; 2018 Oct; 57(10):1178-1181. PubMed ID: 30066970
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics and Safety of Ingenol Disoxate Gel Administered Under Maximum-Use Conditions to Patients With Actinic Keratosis.
    Lain E; Skov T; Hall A
    Clin Drug Investig; 2018 Mar; 38(3):249-257. PubMed ID: 29204958
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Variables in Cryosurgery Technique Associated With Clearance of Actinic Keratosis.
    Berman B; Shabbir AQ; MacNeil T; Knudsen KM
    Dermatol Surg; 2017 Mar; 43(3):424-430. PubMed ID: 28002105
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
    Gupta AK; Paquet M
    J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis.
    Righi V; Tarentini E; Mucci A; Reggiani C; Rossi MC; Ferrari F; Casari A; Magnoni C
    Sci Rep; 2019 Aug; 9(1):11515. PubMed ID: 31395965
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel.
    Segura S; Gadea A; Nonell L; Andrades E; Sánchez S; Pujol R; Hernández-Muñoz I; Toll A
    PLoS One; 2020; 15(5):e0232146. PubMed ID: 32413042
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients.
    Joe HJ; Oh BH
    Clin Cosmet Investig Dermatol; 2017; 10():93-98. PubMed ID: 28408848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.